Sensei Biotherapeutics Q3 net loss $13.4M; cash $116.6M, runway to Q1 2025

Sensei Biotherapeutics, Inc.

2022-Q3 EPS reported -$1.18

Net loss of $13.4M ($0.44/share) vs $9.7M in Q3 2021; R&D expense $9.2M, up from $6.4M.
Cash and marketable securities $116.6M as of Sept 30, 2022; expected to fund operations into Q1 2025.
Suspends ImmunoPhage platform development to focus on TMAb platform for conditionally active antibodies.
On track to submit IND for SNS-101 (anti-VISTA) in H1 2023; preclinical data presented at SITC.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Sensei Biotherapeutics, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-279720

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.